Paris, June 14, 2018 – Medicen Paris Region, Europe’s leading health cluster, today announces the appointment of Stéphane Roques as CEO with approval from the board of directors. He will be in charge of implementing the cluster’s strategy in order to make the Paris region a world leader in the field of life sciences and health.

A graduate from Neoma, Stephane Roques has a degree in sociology. He spent six years at Arthur Andersen, working with public organizations and associations. Roques successively managed well-known organizations in the field of innovation and health (secretary general of AFM-Téléthon, CEO of MSF – Doctors without Borders) and R&D centers of excellence such as the Institute of Myology at Pitié-Salpêtrière and Genethon in Evry. He also chaired the start-up Genosafe and launched the Institute of Biotherapies for Rare Diseases. He is also very involved in civil society and participated in the political movement En Marche!.

“Stéphane will bring a new managerial dimension to the cluster, a wealth of knowledge in the health ecosystem and a pragmatic ambition to further company development in order to make the Paris region one of the world leaders in health,” said Christian Lajoux, president of Medicen Paris Region.

“I am passionate about innovation and health. I have always been committed to serving the public interest alongside public and private actors, whether they be doctors, researchers, patients, entrepreneurs or investors. I am convinced that the convergence of their common interests can shape a new world and be a source of economic and societal value. I am proud to join the Medicen team to take up this formidable challenge,” said Stéphane Roques.

The board of directors also renewed the mandate of the treasurer, the presidencies of the committees for strategic activities areas (DAS Commissions) and requested a new strategic orientation council.

 

About Medicen Paris Region

Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 400 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:

  • Foster the emergence, development and funding of certified collaborative projects in the healthcare sector, in order to create economic value and jobs
  • Increase the international development of innovative startups and SMEs
  • Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences activity in France

Since the creation of the cluster in 2005, 68 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 302 projects. They received funding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion ($2.3bn) and €533 million ($635M) of public aid.

www.medicen.org